Cargando…

OR21-06 Growth Response Of Oral LUM-201 In OraGrowtH210 And OraGrowtH212 Trials In Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data

Disclosure: M.J. Tansey: Research Investigator; Self; Lumos Pharma, Inc. S.A. Bowden: Research Investigator; Self; Lumos Pharma, Inc. A.N. Dauber: Research Investigator; Self; Lumos Pharma, Inc. B. Wikiera: Research Investigator; Self; Lumos Pharma, Inc. B. Pyrzak: Research Investigator; Self; Lumos...

Descripción completa

Detalles Bibliográficos
Autores principales: Tansey, Michael J, Bowden, Sasigarn Arunchaiya, Dauber, Andrew Nahum, Wikiera, Beata, Pyrzak, Beata, Bossowski, Artur T, Petriczko, Elzbieta, Stawerska, Renata, Moszczynska, Elzbieta, Cassorla, Fernando, Feldt, Matthew M, Lunsford, Alison J, Gottschalk, Michael Everett, Marin, Monica, Nayak, Sunil N, Bhuvana, Sunil, Repaske, David Roy, Soyka, Leslie Ann, Fuqua, John S, Escobar, Oscar, Bowlby, Deborah A, Fechner, Patricia Y, Wiltshire, Esko, Harris, Mark, Wintergerst, Kupper A, Lafferty, Antony Richard A, Miller, Bradley S, Simm, Peter, Bruchey, Aleksandra, Smith, Christopher, Karpf, David B, McKew, John C, Thorner, Michael O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554400/
http://dx.doi.org/10.1210/jendso/bvad114.1524
_version_ 1785116404151746560
author Tansey, Michael J
Bowden, Sasigarn Arunchaiya
Dauber, Andrew Nahum
Wikiera, Beata
Pyrzak, Beata
Bossowski, Artur T
Petriczko, Elzbieta
Stawerska, Renata
Moszczynska, Elzbieta
Cassorla, Fernando
Feldt, Matthew M
Lunsford, Alison J
Gottschalk, Michael Everett
Marin, Monica
Nayak, Sunil N
Bhuvana, Sunil
Repaske, David Roy
Soyka, Leslie Ann
Fuqua, John S
Escobar, Oscar
Bowlby, Deborah A
Fechner, Patricia Y
Wiltshire, Esko
Harris, Mark
Wintergerst, Kupper A
Lafferty, Antony Richard A
Miller, Bradley S
Simm, Peter
Bruchey, Aleksandra
Smith, Christopher
Karpf, David B
McKew, John C
Thorner, Michael O
author_facet Tansey, Michael J
Bowden, Sasigarn Arunchaiya
Dauber, Andrew Nahum
Wikiera, Beata
Pyrzak, Beata
Bossowski, Artur T
Petriczko, Elzbieta
Stawerska, Renata
Moszczynska, Elzbieta
Cassorla, Fernando
Feldt, Matthew M
Lunsford, Alison J
Gottschalk, Michael Everett
Marin, Monica
Nayak, Sunil N
Bhuvana, Sunil
Repaske, David Roy
Soyka, Leslie Ann
Fuqua, John S
Escobar, Oscar
Bowlby, Deborah A
Fechner, Patricia Y
Wiltshire, Esko
Harris, Mark
Wintergerst, Kupper A
Lafferty, Antony Richard A
Miller, Bradley S
Simm, Peter
Bruchey, Aleksandra
Smith, Christopher
Karpf, David B
McKew, John C
Thorner, Michael O
author_sort Tansey, Michael J
collection PubMed
description Disclosure: M.J. Tansey: Research Investigator; Self; Lumos Pharma, Inc. S.A. Bowden: Research Investigator; Self; Lumos Pharma, Inc. A.N. Dauber: Research Investigator; Self; Lumos Pharma, Inc. B. Wikiera: Research Investigator; Self; Lumos Pharma, Inc. B. Pyrzak: Research Investigator; Self; Lumos Pharma, Inc. A.T. Bossowski: Research Investigator; Self; Lumos Pharma, Inc. E. Petriczko: Research Investigator; Self; Lumos Pharma, Inc. R. Stawerska: Research Investigator; Self; Lumos Pharma, Inc. E. Moszczynska: Research Investigator; Self; Lumos Pharma, Inc. F. Cassorla: Research Investigator; Self; Lumos Pharma, Inc. Speaker; Self; Lumos Pharma, Inc. M.M. Feldt: Research Investigator; Self; Lumos Pharma, Inc. A.J. Lunsford: Research Investigator; Self; Lumos Pharma, Inc. M.E. Gottschalk: Research Investigator; Self; Lumos Pharma, Inc. M. Marin: Research Investigator; Self; Lumos Pharma, Inc. S.N. Nayak: Research Investigator; Self; Lumos Pharma, Inc. S. Bhuvana: Research Investigator; Self; Lumos Pharma, Inc. D.R. Repaske: Research Investigator; Self; Lumos Pharma, Inc. L.A. Soyka: Research Investigator; Self; Lumos Pharma, Inc. J.S. Fuqua: Research Investigator; Self; Lumos Pharma, Inc. O. Escobar: Research Investigator; Self; Lumos Pharma, Inc. D.A. Bowlby: Research Investigator; Self; Lumos Pharma, Inc. P.Y. Fechner: Research Investigator; Self; Lumos Pharma, Inc. E. Wiltshire: Research Investigator; Self; Lumos Pharma, Inc. M. Harris: Research Investigator; Self; Lumos Pharma, Inc. K.A. Wintergerst: Research Investigator; Self; Lumos Pharma, Inc. A.R. Lafferty: Research Investigator; Self; Lumos Pharma, Inc. B.S. Miller: Research Investigator; Self; Lumos Pharma, Inc. P. Simm: Research Investigator; Self; Lumos Pharma, Inc. A. Bruchey: Employee; Self; Lumos Pharma, Inc. Stock Owner; Self; Lumos Pharma, Inc. C. Smith: Employee; Self; Lumos Pharma, Inc. Stock Owner; Self; Lumos Pharma, Inc. D.B. Karpf: Employee; Self; Lumos Pharma, Inc. Stock Owner; Self; Lumos Pharma, Inc. J.C. McKew: Employee; Self; Lumos Pharma, Inc. Stock Owner; Self; Lumos Pharma, Inc. M.O. Thorner: Consulting Fee; Self; Lumos Pharma, Inc. Stock Owner; Self; Lumos Pharma, Inc. Background: LUM-201 (ibutamoren), a growth hormone (GH) secretagogue receptor 1a (GHSR1a) agonist, is a potent, long-acting investigational oral GH secretagogue currently studied in three Idiopathic Pediatric GH Deficiency (iPGHD) studies. The LUM-201 predictive enrichment marker (PEM) is used to identify patients diagnosed with iPGHD (peak stimulated GH >3<10 ng/mL) who are likely to respond to LUM-201. PEM positivity is defined as a baseline insulin-like growth factor-1 (IGF-1) level >30 ng/mL and a peak GH of ≥5 ng/mL in response to a single 0.8 mg/kg dose of LUM-201. Objectives: Report the growth response analyzing the combined interim analysis (IA) data from two Phase 2 trials studying LUM-201 at two different doses (1.6 mg/kg/day or 3.2 mg/kg/day). Methods: IA data from both studies were combined and analyzed for calculated annualized height velocity (AHV). Baseline demographics were analyzed for the two combined cohorts. Results: After 6 months of treatment with LUM-201, the calculated AHV (mean ±SD ) was 8.1±1.9 cm/year in the 1.6 mg/kg/day group and 8.0±1.5 cm/year in the 3.2 mg/kg/day group (N=15 in both groups). After 9 months of treatment, the calculated AHV was 7.8±1.7 cm/year in the 1.6 mg/kg/day group and 7.3±1.7 cm/year in the 3.2 mg/kg/day group (N=10 in both groups). After 12 months of treatment, the calculated AHV was 7.8±1.7 cm/year in the 1.6 mg/kg/day group and 7.4 ±1.2 cm/year in the 3.2 mg/kg/day group (N=6 in both groups). LUM-201 was well tolerated; no safety concerns were identified across the dose range in adverse events (AE) data, laboratory values, and ECG values. Conclusions: As the growth velocity was comparable for the two doses of oral LUM-201, this analysis of the combined IA data appears to strongly support 1.6 mg/kg/day as the optimal dose for the Phase 3 trial, as doubling the dose appeared to offer no meaningful improvement in efficacy. Final determination will await final full data set analysis of both studies. Presentation: Saturday, June 17, 2023
format Online
Article
Text
id pubmed-10554400
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105544002023-10-06 OR21-06 Growth Response Of Oral LUM-201 In OraGrowtH210 And OraGrowtH212 Trials In Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data Tansey, Michael J Bowden, Sasigarn Arunchaiya Dauber, Andrew Nahum Wikiera, Beata Pyrzak, Beata Bossowski, Artur T Petriczko, Elzbieta Stawerska, Renata Moszczynska, Elzbieta Cassorla, Fernando Feldt, Matthew M Lunsford, Alison J Gottschalk, Michael Everett Marin, Monica Nayak, Sunil N Bhuvana, Sunil Repaske, David Roy Soyka, Leslie Ann Fuqua, John S Escobar, Oscar Bowlby, Deborah A Fechner, Patricia Y Wiltshire, Esko Harris, Mark Wintergerst, Kupper A Lafferty, Antony Richard A Miller, Bradley S Simm, Peter Bruchey, Aleksandra Smith, Christopher Karpf, David B McKew, John C Thorner, Michael O J Endocr Soc Pediatric Endocrinology Disclosure: M.J. Tansey: Research Investigator; Self; Lumos Pharma, Inc. S.A. Bowden: Research Investigator; Self; Lumos Pharma, Inc. A.N. Dauber: Research Investigator; Self; Lumos Pharma, Inc. B. Wikiera: Research Investigator; Self; Lumos Pharma, Inc. B. Pyrzak: Research Investigator; Self; Lumos Pharma, Inc. A.T. Bossowski: Research Investigator; Self; Lumos Pharma, Inc. E. Petriczko: Research Investigator; Self; Lumos Pharma, Inc. R. Stawerska: Research Investigator; Self; Lumos Pharma, Inc. E. Moszczynska: Research Investigator; Self; Lumos Pharma, Inc. F. Cassorla: Research Investigator; Self; Lumos Pharma, Inc. Speaker; Self; Lumos Pharma, Inc. M.M. Feldt: Research Investigator; Self; Lumos Pharma, Inc. A.J. Lunsford: Research Investigator; Self; Lumos Pharma, Inc. M.E. Gottschalk: Research Investigator; Self; Lumos Pharma, Inc. M. Marin: Research Investigator; Self; Lumos Pharma, Inc. S.N. Nayak: Research Investigator; Self; Lumos Pharma, Inc. S. Bhuvana: Research Investigator; Self; Lumos Pharma, Inc. D.R. Repaske: Research Investigator; Self; Lumos Pharma, Inc. L.A. Soyka: Research Investigator; Self; Lumos Pharma, Inc. J.S. Fuqua: Research Investigator; Self; Lumos Pharma, Inc. O. Escobar: Research Investigator; Self; Lumos Pharma, Inc. D.A. Bowlby: Research Investigator; Self; Lumos Pharma, Inc. P.Y. Fechner: Research Investigator; Self; Lumos Pharma, Inc. E. Wiltshire: Research Investigator; Self; Lumos Pharma, Inc. M. Harris: Research Investigator; Self; Lumos Pharma, Inc. K.A. Wintergerst: Research Investigator; Self; Lumos Pharma, Inc. A.R. Lafferty: Research Investigator; Self; Lumos Pharma, Inc. B.S. Miller: Research Investigator; Self; Lumos Pharma, Inc. P. Simm: Research Investigator; Self; Lumos Pharma, Inc. A. Bruchey: Employee; Self; Lumos Pharma, Inc. Stock Owner; Self; Lumos Pharma, Inc. C. Smith: Employee; Self; Lumos Pharma, Inc. Stock Owner; Self; Lumos Pharma, Inc. D.B. Karpf: Employee; Self; Lumos Pharma, Inc. Stock Owner; Self; Lumos Pharma, Inc. J.C. McKew: Employee; Self; Lumos Pharma, Inc. Stock Owner; Self; Lumos Pharma, Inc. M.O. Thorner: Consulting Fee; Self; Lumos Pharma, Inc. Stock Owner; Self; Lumos Pharma, Inc. Background: LUM-201 (ibutamoren), a growth hormone (GH) secretagogue receptor 1a (GHSR1a) agonist, is a potent, long-acting investigational oral GH secretagogue currently studied in three Idiopathic Pediatric GH Deficiency (iPGHD) studies. The LUM-201 predictive enrichment marker (PEM) is used to identify patients diagnosed with iPGHD (peak stimulated GH >3<10 ng/mL) who are likely to respond to LUM-201. PEM positivity is defined as a baseline insulin-like growth factor-1 (IGF-1) level >30 ng/mL and a peak GH of ≥5 ng/mL in response to a single 0.8 mg/kg dose of LUM-201. Objectives: Report the growth response analyzing the combined interim analysis (IA) data from two Phase 2 trials studying LUM-201 at two different doses (1.6 mg/kg/day or 3.2 mg/kg/day). Methods: IA data from both studies were combined and analyzed for calculated annualized height velocity (AHV). Baseline demographics were analyzed for the two combined cohorts. Results: After 6 months of treatment with LUM-201, the calculated AHV (mean ±SD ) was 8.1±1.9 cm/year in the 1.6 mg/kg/day group and 8.0±1.5 cm/year in the 3.2 mg/kg/day group (N=15 in both groups). After 9 months of treatment, the calculated AHV was 7.8±1.7 cm/year in the 1.6 mg/kg/day group and 7.3±1.7 cm/year in the 3.2 mg/kg/day group (N=10 in both groups). After 12 months of treatment, the calculated AHV was 7.8±1.7 cm/year in the 1.6 mg/kg/day group and 7.4 ±1.2 cm/year in the 3.2 mg/kg/day group (N=6 in both groups). LUM-201 was well tolerated; no safety concerns were identified across the dose range in adverse events (AE) data, laboratory values, and ECG values. Conclusions: As the growth velocity was comparable for the two doses of oral LUM-201, this analysis of the combined IA data appears to strongly support 1.6 mg/kg/day as the optimal dose for the Phase 3 trial, as doubling the dose appeared to offer no meaningful improvement in efficacy. Final determination will await final full data set analysis of both studies. Presentation: Saturday, June 17, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554400/ http://dx.doi.org/10.1210/jendso/bvad114.1524 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Pediatric Endocrinology
Tansey, Michael J
Bowden, Sasigarn Arunchaiya
Dauber, Andrew Nahum
Wikiera, Beata
Pyrzak, Beata
Bossowski, Artur T
Petriczko, Elzbieta
Stawerska, Renata
Moszczynska, Elzbieta
Cassorla, Fernando
Feldt, Matthew M
Lunsford, Alison J
Gottschalk, Michael Everett
Marin, Monica
Nayak, Sunil N
Bhuvana, Sunil
Repaske, David Roy
Soyka, Leslie Ann
Fuqua, John S
Escobar, Oscar
Bowlby, Deborah A
Fechner, Patricia Y
Wiltshire, Esko
Harris, Mark
Wintergerst, Kupper A
Lafferty, Antony Richard A
Miller, Bradley S
Simm, Peter
Bruchey, Aleksandra
Smith, Christopher
Karpf, David B
McKew, John C
Thorner, Michael O
OR21-06 Growth Response Of Oral LUM-201 In OraGrowtH210 And OraGrowtH212 Trials In Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data
title OR21-06 Growth Response Of Oral LUM-201 In OraGrowtH210 And OraGrowtH212 Trials In Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data
title_full OR21-06 Growth Response Of Oral LUM-201 In OraGrowtH210 And OraGrowtH212 Trials In Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data
title_fullStr OR21-06 Growth Response Of Oral LUM-201 In OraGrowtH210 And OraGrowtH212 Trials In Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data
title_full_unstemmed OR21-06 Growth Response Of Oral LUM-201 In OraGrowtH210 And OraGrowtH212 Trials In Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data
title_short OR21-06 Growth Response Of Oral LUM-201 In OraGrowtH210 And OraGrowtH212 Trials In Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data
title_sort or21-06 growth response of oral lum-201 in oragrowth210 and oragrowth212 trials in idiopathic pediatric growth hormone deficiency (ipghd): combined analysis interim analysis data
topic Pediatric Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554400/
http://dx.doi.org/10.1210/jendso/bvad114.1524
work_keys_str_mv AT tanseymichaelj or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT bowdensasigarnarunchaiya or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT dauberandrewnahum or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT wikierabeata or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT pyrzakbeata or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT bossowskiarturt or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT petriczkoelzbieta or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT stawerskarenata or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT moszczynskaelzbieta or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT cassorlafernando or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT feldtmatthewm or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT lunsfordalisonj or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT gottschalkmichaeleverett or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT marinmonica or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT nayaksuniln or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT bhuvanasunil or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT repaskedavidroy or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT soykaleslieann or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT fuquajohns or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT escobaroscar or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT bowlbydeboraha or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT fechnerpatriciay or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT wiltshireesko or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT harrismark or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT wintergerstkuppera or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT laffertyantonyricharda or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT millerbradleys or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT simmpeter or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT brucheyaleksandra or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT smithchristopher or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT karpfdavidb or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT mckewjohnc or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata
AT thornermichaelo or2106growthresponseoforallum201inoragrowth210andoragrowth212trialsinidiopathicpediatricgrowthhormonedeficiencyipghdcombinedanalysisinterimanalysisdata